Intangible Asset	9 Months Ended
Intangible Asset	Sep. 30, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 8 – Intangible Asset On June 13, 2011, the Company entered into a Purchase and Exclusive Marketing Agreement (“Agreement”) with Imagenetix, Inc. (“Imagenetix”), Proprietary Nutritionals, Inc. (“Proprietary”) and Pharmachem Laboratories, Inc. (with Imagenetix and Proprietary, “PNI”) pursuant to which the Company was granted perpetual exclusive United States rights to purchase from PNI their Celadrin products and brand (“Celadrin”) as well as exclusive marketing and distribution and related rights in the U.S. During the term of the Agreement, the Company has the right to purchase Celadrin from PNI for use in the U.S. at a purchase price equal to the then agreed upon wholesale prices at a 2% discount, with a net 60 days payment term. Prices can be increased in any January for the next year by no more than the then consumer price index or 5% whichever is greater. The Company agreed to issued $800,000 of its common stock in exchange for the marketing and distribution rights on February 1, 2012, which is six months after the date of execution of the Agreement. The transaction was recorded as an intangible asset and is amortized over the estimated useful life of fifteen years. Amortization was $13,333 and $0 for the three months ended September 30, 2011 and 2010, respectively and $15,556 and $0 for the nine months ended September 30, 2011 and 2010, respectively.

LTS Nutraceuticals, Inc. 10-Q